Literature DB >> 8709276

Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures.

R L Willey1, R Shibata, E O Freed, M W Cho, M A Martin.   

Abstract

Two primary cell targets for human immunodeficiency virus type 1 (HIV-1) infection in vivo are CD4+ T lymphocytes and monocyte-derived macrophages (MDM). HIV-1 encodes envelope glycoproteins which mediate virus entry into these cells. We have utilized infected and radiolabelled primary peripheral blood mononuclear cell (PBMC) and MDM cultures to examine the biochemical and antigenic properties of the HIV-1 envelope produced in these two cell types. The gp120 produced in MDM migrates as a broad, diffuse band in sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels compared with that of the more homogeneous gp120 released from PBMCs. Glycosidase analyses indicated that the diffuse appearance of the MDM gp120 is due to the presence of asparagine-linked carbohydrates containing lactosaminoglycans, a modification not observed with the gp120 produced in PBMCs. Neutralization experiments, using isogeneic PBMC and MDM-derived macrophage-tropic HIV-1 isolates, indicate that 8- to 10-fold more neutralizing antibody, directed against the viral envelope, is required to block virus produced from MDM. These results demonstrate that HIV-1 released from infected PBMC and MDM cultures differs in its biochemical and antigenic properties.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8709276      PMCID: PMC190674          DOI: 10.1128/JVI.70.9.6431-6436.1996

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Intracellular processing of the gp160 HIV-1 envelope precursor. Endoproteolytic cleavage occurs in a cis or medial compartment of the Golgi complex.

Authors:  B S Stein; E G Engleman
Journal:  J Biol Chem       Date:  1990-02-15       Impact factor: 5.157

Review 2.  Glycobiology.

Authors:  T W Rademacher; R B Parekh; R A Dwek
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

3.  Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization.

Authors:  J E Hansen; H Clausen; C Nielsen; L S Teglbjaerg; L L Hansen; C M Nielsen; E Dabelsteen; L Mathiesen; S I Hakomori; J O Nielsen
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

4.  Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120.

Authors:  H Geyer; C Holschbach; G Hunsmann; J Schneider
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

5.  Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.

Authors:  R L Willey; J S Bonifacino; B J Potts; M A Martin; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

6.  Molecular cloning and amino acid sequence of peptide-N4-(N-acetyl-beta-D-glucosaminyl)asparagine amidase from flavobacterium meningosepticum.

Authors:  A L Tarentino; G Quinones; A Trumble; L M Changchien; B Duceman; F Maley; T H Plummer
Journal:  J Biol Chem       Date:  1990-04-25       Impact factor: 5.157

7.  Replication of HIV-1 in primary monocyte cultures.

Authors:  B J Potts; W Maury; M A Martin
Journal:  Virology       Date:  1990-04       Impact factor: 3.616

8.  Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1.

Authors:  E Fenouillet; J C Gluckman; E Bahraoui
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

9.  Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.

Authors:  Y Koyanagi; S Miles; R T Mitsuyasu; J E Merrill; H V Vinters; I S Chen
Journal:  Science       Date:  1987-05-15       Impact factor: 47.728

10.  Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes.

Authors:  H E Gendelman; J M Orenstein; M A Martin; C Ferrua; R Mitra; T Phipps; L A Wahl; H C Lane; A S Fauci; D S Burke
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

View more
  31 in total

1.  The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.

Authors:  T Murakami; E O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC.

Authors:  Tara G Edmonds; Haitao Ding; Xing Yuan; Qing Wei; Kendra S Smith; Joan A Conway; Lindsay Wieczorek; Bruce Brown; Victoria Polonis; John T West; David C Montefiori; John C Kappes; Christina Ochsenbauer
Journal:  Virology       Date:  2010-09-21       Impact factor: 3.616

3.  Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques.

Authors:  W M Blay; S Gnanakaran; B Foley; N A Doria-Rose; B T Korber; N L Haigwood
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1.

Authors:  Claudia Cicala; Elena Martinelli; Jonathan P McNally; Diana J Goode; Ravindra Gopaul; Joseph Hiatt; Katija Jelicic; Shyamasundaran Kottilil; Katilyn Macleod; Angeline O'Shea; Nikita Patel; Donald Van Ryk; Danlan Wei; Massimiliano Pascuccio; Ling Yi; Lyle McKinnon; Preson Izulla; Joshua Kimani; Rupert Kaul; Anthony S Fauci; James Arthos
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-20       Impact factor: 11.205

5.  The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant.

Authors:  Nicholas M Provine; Valerie Cortez; Vrasha Chohan; Julie Overbaugh
Journal:  Virology       Date:  2012-02-25       Impact factor: 3.616

6.  Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus.

Authors:  T Igarashi; Y Endo; G Englund; R Sadjadpour; T Matano; C Buckler; A Buckler-White; R Plishka; T Theodore; R Shibata; M Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

7.  Structure and Immune Recognition of the HIV Glycan Shield.

Authors:  Max Crispin; Andrew B Ward; Ian A Wilson
Journal:  Annu Rev Biophys       Date:  2018-03-29       Impact factor: 12.981

8.  Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay.

Authors:  Ronald Willey; Martha C Nason; Yoshiaki Nishimura; Dean A Follmann; Malcolm A Martin
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

9.  sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.

Authors:  Laurel A Lagenaur; Vadim A Villarroel; Virgilio Bundoc; Barna Dey; Edward A Berger
Journal:  Retrovirology       Date:  2010-02-16       Impact factor: 4.602

10.  HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activity.

Authors:  Nobuyuki Matoba; Adam S Husk; Brian W Barnett; Michelle M Pickel; Charles J Arntzen; David C Montefiori; Atsushi Takahashi; Kazunobu Tanno; Satoshi Omura; Huyen Cao; Jason P Mooney; Carl V Hanson; Haruo Tanaka
Journal:  PLoS One       Date:  2010-06-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.